Avantor, Inc.
AVTR- Exchange
- NYSE
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001722482
No open-market purchases or sales by Avantor, Inc. insiders were filed in the last 90 days; 460 institutions reported holding it in 13F filings for Q2 2026, worth $6.92B in total; superinvestors Greenhaven Associates and Southeastern Asset Management (Longleaf) hold it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Avantor, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Avantor, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Garner Todd W | EVP and CFO | 49,688 | Sep 23, 2026 | 1 |
| Ligner Emmanuel | President and CEO | 737,334 | Aug 20, 2026 | 3 |
| Hankamer Brittany | EVP, Chief HR Officer | 248,864 | Aug 18, 2026 | 3 |
| Eck Steven W | SVP & Chief Accounting Officer | 129,593 | Aug 4, 2026 | 4 |
| Sokenu Claudius | EVP, Chief Legal & Compliance | 251,228 | Jul 27, 2026 | 3 |
| Walker Corey | President, VWR Dist. & Servs. | 384,535 | Jun 22, 2026 | 2 |
| Mehra Sanjeev K | Director | 33,376 | May 11, 2026 | 3 |
| Summe Gregory L | Director | 83,381 | May 11, 2026 | 3 |
| Lucier Gregory T | Director | 60,000Indirect | May 11, 2026 | 3 |
| Massaro Joseph R | Director | 77,408 | May 11, 2026 | 1 |
| Severino Michael | Director | 85,821 | May 11, 2026 | 1 |
| Murthy Mala | Director | 69,479 | May 11, 2026 | 1 |
| Makin Louise | Director | 47,140 | May 11, 2026 | 1 |
| Dingemans Simon | Director | 31,495 | May 11, 2026 | 3 |
| Brellier Ludovic | EVP, Bioscience & Medtech | 146,566 | May 5, 2026 | 1 |
| Jones R. Brent | EVP, Chief Financial Officer | 419,782 | Feb 25, 2026 | 2 |
| Gourdier Benoit | EVP, Bioscience & Medtech | 362,859 | Feb 25, 2026 | 3 |
| Blenn Mary | EVP, Chief Operating Officer | 253,384 | Feb 23, 2026 | 2 |
| Couturier Christophe | EVP, AMEA | 211,271 | Aug 12, 2025 | 0 |
| Stubblefield Michael | President & CEO | 545,500Indirect | May 21, 2025 | 0 |
| Peacock Jonathan M | Director | 219,815 | May 12, 2025 | 0 |
| Andres Juan | Director | 65,480 | May 12, 2025 | 0 |
| Kang Lan | Director | 52,315 | May 12, 2025 | 0 |
| Carethers John | Director | 45,858 | May 12, 2025 | 0 |
| Bramwell James | EVP Sales, Customer Excellence | 86,605 | Feb 28, 2025 | 0 |
| Sahin Kitty | EVP, Strategy&Corp Development | 42,274 | Jul 22, 2024 | 0 |
| Stone Randy Lee | EVP, Laboratory Solutions | 68,105 | Apr 18, 2024 | 0 |
| Lewis Sheri | EVP, Global Ops & Supply Chain | 70,692 | Jan 3, 2024 | 0 |
| Vanderhaegen Frederic | EVP, Americas and Europe | 160,735 | Aug 28, 2023 | 0 |
| Szlosek Thomas A | EVP & CFO | 77,489 | May 19, 2023 | 0 |
| Brophy Gerard | EVP, Biopharma Production | 89,032 | May 19, 2023 | 0 |
| Miller Justin | EVP & General Counsel | 93,336 | May 19, 2023 | 0 |
| Shaw Christi | Director | 36,271 | May 15, 2023 | 0 |
| Henson Meghan | EVP, Chief HR Officer | 40,184 | Feb 27, 2023 | 0 |
| Wondrasch Michael | EVP & CIO | 96,072 | Feb 22, 2023 | 0 |
| Holt Matthew S. | Director | 7,908 | May 16, 2022 | 0 |
| Gupta Rajiv | Director | 780,562 | Apr 5, 2022 | 0 |
| Murray Mark Christopher | EVP, Biomaterials & AT | 18,680 | Jan 18, 2022 | 0 |
| Natauri Jo | Director | 557,656Indirect | Aug 13, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 (view filing) | Aug 26 | 1 day | Eck Steven WSVP & Chief Accounting Officer | SSale | −17.4K | $40.08 | −$696.7K | −55.1%14.1K after | |
| Aug 23, 2021 (view filing) | Aug 20 | 3 days | Gupta RajivDirector | SSale | −100.0K | $38.81 | −$3.88M | −7.2%1.28M after | |
| Aug 13, 2021 (view filing) | Jul 12 | 32 daysLate | Natauri JoDirector | PPurchaseCommon Stock, par value $0.01 per share | +300 | $36.33 | +$10.9K | +0.1%557.7K after | |
| Aug 2, 2021 (view filing) | Jul 30 | 3 days | Brophy GerardEVP, Biopharma Production | SSale | −81.1K | $37.24 | −$3.02M | −35.2%149.4K after | |
| Jul 21, 2021 (view filing) | Jul 20 | 1 day | Bramwell JamesEVP, Strategic Partners | SSale | −6.11K | $37.00 | −$226.1K | −7.1%79.9K after | |
| Jul 13, 2021 (view filing) | Jul 9 | 4 days | Bramwell JamesEVP, Strategic Partners | SSale | −18.3K | $35.61 | −$652.8K | −17.6%86.0K after | 2 lots |